Stem cell therapy safety depends entirely on what type of treatment you’re talking about. Established stem cell transplants used in cancer care have decades of safety data and clear, well-documented risks. Newer experimental injections for joint pain or anti-aging, many offered at private clinics, range from relatively low-risk to genuinely dangerous. The gap between these two worlds is enormous, and understanding it is the key to answering this question.
Proven Stem Cell Treatments and Their Risks
Hematopoietic stem cell transplants, where blood-forming stem cells replace a patient’s damaged bone marrow, are a standard treatment for blood cancers like leukemia and lymphoma. The FDA has approved several cord blood stem cell products for this purpose. These transplants save lives, but they are serious medical procedures with real risks.
When you receive your own stem cells back (autologous transplant), the procedure is safer. Non-relapse mortality, meaning death from the transplant itself rather than the disease, runs between 1% and 3% for conditions like multiple myeloma. Five-year survival rates for autologous transplants reach roughly 75% for multiple myeloma and 80% to 90% for Hodgkin lymphoma patients with chemo-sensitive relapse.
When stem cells come from a donor (allogeneic transplant), risk rises substantially. The biggest added danger is graft-versus-host disease, where the donor’s immune cells attack your body. Across clinical studies, acute graft-versus-host disease affects roughly 20% to 50% of recipients, and chronic forms develop in 17% to 67% depending on the study. Transplant-related mortality for donor transplants can reach 16% to 36% for certain blood cancers. These are not minor numbers, but for patients with aggressive cancers, the alternative is often worse.
Survivors of either type of transplant need lifelong monitoring. The conditioning regimens used to prepare the body, typically intensive chemotherapy or radiation, cause lasting tissue damage. The 15-year cumulative incidence of severe or life-threatening chronic health conditions in transplant survivors exceeds 40%. Late complications can affect the heart, lungs, kidneys, liver, bones, eyes, hormones, and fertility, and there is an elevated risk of secondary cancers years later.
Stem Cell Injections for Joint Pain
The most common reason people search about stem cell safety is probably joint injections, particularly for knee osteoarthritis. This is a different universe from cancer transplants. The procedures are outpatient, involve far fewer cells, and skip the brutal conditioning regimens.
A systematic review of nearly 2,000 patients receiving stem cell injections for knee osteoarthritis found an overall 12.3% rate of transient adverse events, mostly swelling and pain at the injection site. No serious adverse events were reported across the entire group. For context, hyaluronic acid injections (a common conventional treatment) have a reported adverse event rate around 27.7%, and corticosteroid injections sit around 14.3%. So stem cell injections for knees appear comparable to, or milder than, treatments already in widespread use.
The source of the cells matters, though. Bone marrow-derived stem cells had a 10.7% adverse event rate. Cells derived from processed fat tissue had an 8.1% rate. Cultured fat-derived cells jumped to 29.5%, and umbilical cord-derived cells had the highest rate at 51.7%. Pain or swelling lasting longer than four weeks was rare, occurring in less than 1% of patients across all cell types. One meta-analysis concluded that the human body tolerates mesenchymal stem cells well and that stem cell treatment for knee osteoarthritis has no obvious additional side effects compared to conventional approaches.
The Tumor Risk With Certain Cell Types
One of the more alarming risks in stem cell science involves a specific cell type: induced pluripotent stem cells (iPSCs). These are adult cells reprogrammed back into a flexible, embryonic-like state. Their power is also their danger. If even a tiny fraction of undifferentiated iPSCs survive in a batch of cells meant for transplant, they can form tumors called teratomas.
Animal studies have shown this risk is not theoretical. In one experiment, as few as 200,000 residual iPSCs injected intravenously were enough to produce teratomas. Tumors appeared in the spine, brain, kidney, and liver within four to five weeks. Teratomas grew larger in nervous tissue than in abdominal organs, suggesting these cells have a natural preference for certain environments. If a therapeutic cell batch contained just 0.1% residual iPSCs, that could be enough to trigger tumor formation.
This risk applies specifically to iPSC-derived therapies, which are still largely experimental. It does not apply to the mesenchymal stem cells used in most joint injections or the hematopoietic stem cells used in cancer transplants. Researchers are developing methods to purge residual iPSCs before transplantation, and some chemical pretreatments have successfully eliminated teratoma formation in animal models. But this remains an active area of concern as iPSC-based therapies move toward clinical use.
The Unregulated Clinic Problem
Hundreds of clinics across the United States market stem cell treatments for conditions ranging from arthritis to Parkinson’s disease to erectile dysfunction. Most of these treatments have not been evaluated or approved by the FDA. As recently as February 2026, the FDA issued a warning letter to Dynamic Stem Cell Therapy for selling unapproved biological products. This is part of an ongoing enforcement effort that has targeted numerous clinics over the past several years.
The FDA currently approves a limited number of stem cell products, primarily cord blood preparations for hematopoietic transplantation and one product (Ryoncil) for a specific transplant complication. Everything else is either in clinical trials or being sold outside the regulatory framework. Clinics offering unapproved treatments may use cells that haven’t been properly tested for contamination, may process cells in ways that alter their behavior unpredictably, or may inject them into parts of the body where safety has never been studied.
The International Society for Stem Cell Research maintains guidelines calling for rigor, oversight, and transparency, emphasizing that therapies should be evidence-based. When a clinic offers stem cell treatment for a condition where no large clinical trials exist, you’re essentially paying to be an unmonitored test subject, without the safety protections a formal clinical trial would provide.
Factors That Affect Your Personal Risk
If you’re considering a legitimate stem cell procedure, several factors influence how safe it will be for you. Age is one of the most significant. Older patients face higher complication rates, particularly for transplants involving conditioning regimens. Baseline physical fitness matters too; patients in better overall health before treatment tolerate procedures more successfully.
Existing health conditions change the risk calculus. Patients with heart, lung, liver, or kidney problems may not tolerate intensive conditioning. Previous radiation exposure and extensive prior chemotherapy both increase vulnerability to transplant-related damage. For these higher-risk patients, doctors often use reduced-intensity conditioning, which causes less organ damage but carries a higher chance of disease relapse.
The source of the stem cells also shapes risk. Your own cells eliminate the possibility of graft-versus-host disease entirely. Donor cells offer certain therapeutic advantages, particularly a graft-versus-cancer effect, but come with the significant trade-off of immune complications. For joint injections specifically, bone marrow and processed fat tissue appear to have the mildest side effect profiles based on current data.
What “Safe” Actually Means Here
Stem cell therapy is not one thing. A bone marrow transplant for leukemia is a life-saving procedure with substantial, well-characterized risks that doctors have managed for decades. A knee injection with your own bone marrow concentrate appears to carry mild, short-lived side effects in most patients. An unproven treatment at a cash-pay clinic for a neurological condition is a gamble with unknown odds.
The clearest safety data exists for hematopoietic transplants and, increasingly, for mesenchymal stem cell joint injections. Both show manageable risk profiles when performed in appropriate medical settings with proper cell handling. The danger rises sharply when treatments use poorly characterized cell types, target conditions with no supporting clinical evidence, or operate outside regulatory oversight.